- Ustekinumab is effective in biological refractory Crohn's disease patients–regardless of approval study selection criteria
-
Saman S, Goetz M, Wendler J, Malek NP, Wehkamp J, Klag T
- KMID: 2454742
- Intest Res.
- 2019 Jul;17(3):340-348.
- doi: 10.5217/ir.2019.00012
BACKGROUND/AIMS: Ustekinumab is effective in active Crohn's disease. In a retrospective study, we assessed the clinical outcome in nonresponders to anti-tumor necrosis factor therapy, and/or conventional therapy and/or the α4β7-integrin... -
- CITED
-
- Close
- SHARE
-
- Close
